INTRODUCTION
The phosphoinositide 3-kinase (PI3K) family includes 4 isoforms: PI3Ka, PI3Kb, PI3Kd, and PI3Kc. 1, 2 PI3Ks phosphorylate the 3 0 -hydroxyl group of phosphoinositides in response to extracellular signals derived from receptor tyrosine kinases or G-protein-coupled receptors. PI3K signaling regulates multiple processes connected to cellular metabolism, growth, and differentiation; and aberrant activation of the PI3K pathway occurs in a variety of tumors. 1, 3 The oncogenic effect is frequently exacerbated by loss-of-function mutations in the negative regulator of the PI3K pathway, phosphatase and tensin homologue (PTEN). 4 Although the reliance of PTEN-null tumors on the PI3K isoform can be affected by concurrent oncogenic alterations, many PTEN-null tumors depend primarily on activity of the PI3Kb isoform, making this isoform an attractive therapeutic target for PTEN-negative tumors. 1, [5] [6] [7] [8] Because pan-PI3K inhibitors have a limited effect on the PI3Kb isoform at clinically achievable concentrations, selective inhibitors are being developed for the treatment of PTEN-deficient malignancies.
SAR260301 is a potent, selective inhibitor of the PI3Kb isoform (half-maximal inhibitory concentration [IC 50 ], 52 nM) that blocks PI3K signaling in PTEN-null tumors. 7 Although SAR260301 had only marginal activity in preclinical studies when used as single agent, it demonstrated synergistic activity when combined with v-Raf murine sarcoma viral oncogene homolog B (BRAF) or mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase inhibitors against PTEN-negative/BRAF valine-to-glutamic acid mutation at position 600 (BRAF V600E ) melanoma models. 9 The PI3Kb isoform is involved in regulating platelet function. 10 Platelet-derived ex vivo systems can be used to demonstrate PI3Kb-mediated target engagement in patients receiving selective inhibitors. 11 This phase 1, first-in-human study investigated the maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics, and efficacy of the selective PI3Kb inhibitor SAR260301 (clinicaltrials. gov identifier NCT01673737).
MATERIALS AND METHODS

Study Design
This open-label, first-in-human, dose-escalation study evaluated SAR260301 received as monotherapy by patients with locally advanced or metastatic solid tumors. The primary objective was to determine the MTD of SAR260301 administered orally once or twice daily to patients with solid tumors. Secondary objectives included evaluations of safety; PK, including the effects of food; pharmacodynamic properties in the PI3K signaling pathway; and preliminary efficacy. The pharmacodynamic impact of SAR260301 on the PI3K pathway was evaluated using platelet-rich plasma (PRP) as surrogate tissue.
SAR260301 was formulated in 100-mg, film-coated tablets and was administered orally either once or twice daily in 28-day cycles. The following daily doses were investigated sequentially: 100 mg once daily, 100 mg twice daily, 200 mg twice daily, 400 mg twice daily, 600 mg twice daily, and 440 mg/m 2 (approximately 800 mg) twice daily. The starting dose of 100 mg once daily was based on one-eighth of the highest, nonseverely toxic dose tested in dogs. Flat doses were initially administered, but subsequent doses were adjusted to body surface area (BSA) to control for variations in exposure correlated to BSA (data not shown). Patients were to receive all doses in fasting conditions: 1 hour before breakfast and after an overnight fast, and at least 2 hours after an afternoon snack and either 1 hour before dinner or 2 hours after dinner. Patients who participated in the food-effect substudy were to take SAR260301 within 30 minutes of a moderate-fat breakfast (fed condition) on a convenient day in cycle 2. Treatment continued until unacceptable toxicity, progression, or death and could be stopped at any time upon patient's request.
The protocol was approved by all involved independent ethics committees and institutional review boards. The clinical trial was conducted in compliance with all applicable international and national laws and regulations and adhered to the principles outlined in the Helsinki declaration. Written, informed consent was obtained from each patient before study participation.
Study Population
Enrollment included patients with locally advanced or metastatic solid tumors for which no alternative therapy was available. Eligible patients were aged 18 years, had an Eastern Cooperative Oncology Group performance status 1, adequate organ function, and at least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), 12 with archived primary tumor, recurrent tumor, metastasis biopsies, or surgical specimens and at least 75 lm of formalin-fixed, paraffinembedded tissue or a tissue block available. Patients were excluded if they had a risk of bleeding: platelet count <100 , 122 seconds using collagen/adenosine diphosphate (ADP) and/or >183 seconds using the collagen/epinephrine cartridge), prothrombin time (PT)/international normalized ratio or PT >1.3 times the upper limit of normal, recent major surgery (28 days), or active pathologies that could lead to bleeding. In the escalation phase, inclusion was not restricted to PTEN-deficient tumors but was enriched for patients who had tumor types with a known, high prevalence of PTEN deficiency.
Dose-Limiting Toxicity and MTD
The primary safety endpoint was the incidence of doselimiting toxicities (DLTs) at cycle 1 (days 1-28). A DLT was defined as any of the following: grade 3 toxicities (excluding grade 3 nausea and vomiting that resolved to grade 1 within 48 hours or grade 3 diarrhea, if controlled with adequate antidiarrheal therapy and lasting less than 48 hours); inability to administer 25% of SAR260301 (14 doses with twice-daily dosing or 7 doses with once-daily dosing) during cycle 1 because of toxicity; or an adverse event (AE) that did not meet these criteria but was considered dose-limiting by the study committee. If multiple toxicities were observed, then the presence of DLT was based on the most severe toxicity experienced.
Original Article
The maximum increase in dose from 1 level to the next was 100%; if 2 or more patients in the current cohort had grade 2 treatment-related toxicity or if any patient had a DLT, then the maximum increase in dose level could not exceed 50%. Enrolment at the next dose level proceeded only if a minimum of 3 patients completed treatment without a DLT at the current dose level for at least the duration of 1 cycle. It was anticipated that from 25 to 30 DLTevaluable patients would be enrolled. A DLT-evaluable patient received at least 75% dosing within the first 28-day cycle unless the patient discontinued the study drug because of a DLT. The MTD was defined as the highest dose with a tolerable global safety profile, controlling for the risks of overdose and the risks of unacceptable toxicity (for further details, see Statistical Considerations, below).
Safety Assessments
Safety assessments included characterization of the type, frequency, severity, timing, and relation to study therapy of AEs, abnormalities of physical findings, laboratory tests, vital signs, electrocardiograms or left ventricular ejection fraction evaluations, and drug discontinuation because of AEs or serious AEs (SAEs). AEs were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.03. 13 
PK Assessments
Blood samples were collected using dried-blood-spot technology during cycle 1 at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after the first daily administration on days 1 and 28 and on a selected day of cycle 2 for the food-effect pilot study. Additional blood samples were collected before the first daily dose on days 2, 8, 15, and 29 (corresponding to day 1 of cycle 2).
SAR260301 venous blood concentrations were determined using a validated liquid chromatographymass spectrometry/mass spectrometry method with a lower limit of quantification of 1.00 ng/mL. SAR260301 concentrations were used to determine the following PK parameters on days 1 and 28 of cycle 1 in fasted conditions and on a selected day of cycle 2 in fed conditions using standard, noncompartmental analysis: maximum blood concentration observed (C max ), time to reach C max (t max ), area under the blood concentration versus time curve over a 12-hour dosing interval (AUC s ), apparent total body clearance at steady state (CL ss /F), the day 28/day 1 accumulation ratio of AUC s and C max , and the food-effect ratio (fed cycle 2/fast day 28 of cycle 1) of AUC s and C max .
Physiologically-Based PK Modeling
A physiologically-based pharmacokinetic (PBPK) model was built using in silico tool (Simcyp Limited, Sheffield, UK). The model was defined using transporter Pglycoprotein and metabolism enzyme (CYP3A4, 3A5, and UGT 1A9) kinetic saturation data (V max /km) and PK data from patients who received doses from 100 to 400 mg. The model was validated against observed data up to 600 mg and was used to predict the probability of maintaining SAR260301 concentrations sufficient to lead to near-complete PI3K pathway inhibition in PRP, which were anticipated to lead to antitumor activity. PRP preparation and ex vivo determination of the platelet phosphorylated protein kinase B (pAkt) IC 50 were performed according to the instructions provided in Meso Scale Discovery's Phospho (Ser473)/total Akt (tAkt) whole cell lysate kit (catalog no. K15100D-2; Meso Scale Diagnostics, Rockville, MD) (Supporting Methods; see online supporting information).
Pharmacodynamic Assessments
Blood samples were obtained to document the pharmacodynamic effect of SAR260301 on the PI3K pathway. Blood samples were collected into 1 8.5-mL BD Vacutainer ACD A tubes (Becton, Dickenson and Company, Franklin Lakes, NJ) at various time points within cycle 1 (predose on days 1, 2, 15, and 28 and at 1 hour and 6 hours after SAR2060301 administration on days 1 and 28) and were processed to obtain PRP and a frozen platelet pellet, as described above. Lysate prepared from platelet pellet was used to determine the level of pAkt normalized against tAkt for each time point using the Meso Scale Discovery whole-cell assay kit (Meso Scale Diagnostics). Starting from the 400-mg twice-daily dose level, whole-blood samples were collected to explore the impact of SAR260301 on platelet function with the point-of-care PFA100 assay using collagen/epinephrine cartridges. Blood was aspirated from the specimen into the cartridge through a microscopic aperture cut into a biologically active membrane coated with collagen and epinephrine, which induced a platelet plug formation. The time required to close the aperture reflected any defects of the platelet function in the specimen. CT was measured at screening and predose on days 1, 15, and 28; at 1 hour, 3 hours, or 6 hours and at 24 hours postdose on days 1 and 28.
Efficacy Assessments
Preliminary antitumor activity was assessed according to RECIST 1.1 using magnetic resonance imaging or computed tomography at least every 2 cycles. The efficacy endpoint was the overall response rate, which we calculated as the rate of complete response (CR) plus the rate of partial response assessed on efficacy-evaluable patients. The efficacy population was defined as all patients who received at least 1 cycle of the investigational drug and had data available for the baseline assessment and at least 1 postbaseline assessment. Patients who had early progression according to RECIST 1.1 also were included in this set.
Tumor PTEN Expression PTEN status was determined retrospectively by immunohistochemistry (IHC) using the most recent formalinfixed, paraffin-embedded archival tumor tissue sections (5 lM). A research-use-only, validated PTEN assay based on the primary anti-PTEN Cell Signaling Technology antibody (catalog no. 9188; Cell Signaling Technology, Danvers, MA), was used. PTEN analyses were carried out using the Ventana BenchMark XT staining platform (Ventana, Tucson, AZ). Nuclear PTEN immunoreactivity was assessed manually by a pathologist for the percentage of cells that were stained positive and the staining intensity and was calculated as the H-score. An H-score 10 was defined as loss of PTEN.
Statistical Considerations
A Bayesian adaptive design with overdose control was used to provide dose recommendations on SAR260301 dose escalation. A Bayesian logistic regression model 14 was built to assess the DLT rate as a function of dose and was updated based on the observed DLTs within the first 28-day cycle. The dose-escalation design was based on the assessed probability of DLT, aiming for a target DLT rate ranging from 16% to 33%. Dose escalation was indicated if the probability of DLT within this targeted interval at the next level was greater than that at the current level and provided that overdose was controlled. Overdose was deemed to be controlled when both the probability of overdosing (>33% DLT rate) was inferior to 25% and the probability of unacceptable toxicity (>60% DLT) was inferior to 5%. Dose de-escalation was recommended if the probability of DLT within the targeted interval at a lower level was greater than that at the current level. Otherwise, subsequent patients were treated at the current dose level. Intrapatient dose escalation was not allowed.
Role of the Funding Source
The study (NCT01673737) was sponsored by Sanofi. Sanofi contributed to the study design, data analysis and interpretation, and critically reviewed the article. All authors had access to the study data and were responsible for the decision to submit for publication.
RESULTS
Patient Population
In total, 21 patients with metastatic solid tumors were enrolled between August 2012 and July 2014 and were treated with SAR260301 ( Table 1 ). The median age of participants was 61 years, and patients had an Eastern Cooperative Oncology Group performance status of 0 or 1. Only 3 patients (14%) had PTEN-null malignant disease (confirmed by central IHC). Patients had received a median of 4 prior anticancer therapies (range, 1-9 prior anticancer therapies). The median time from initial diagnosis and date of the first study treatment dose for all patients was 4.5 years (range, 1.3-22.2 years). The following doses of SAR260301 were received: 100 mg once daily, 100 mg twice daily, 200 mg twice daily (3 patients each), 400 mg twice daily (6 patients), 600 mg twice daily (4 patients), and 440 mg/m 2 twice daily (2 patients). Patients received a median of 2 cycles (range, 1-8 cycles), and the median cumulative dose was 23.2 g (range, 2.7-337.0 g). Original Article
DLT and MTD
Two DLTs occurred during dose escalation: grade 3 pneumonitis (at 400 mg twice daily) and a grade 3 cglutamyltransferase (GGT) increase (at 600 mg twice daily). Grade 3 pneumonitis occurred in a patient who discontinued the study after cycle 1 because of disease progression. Pneumonitis (initially grade 1) was detected radiologically at the time of tumor assessment, during which disease progression leading to treatment discontinuation was detected. Eighteen days after the last SAR260301 administration, the event worsened to grade 3. Bronchial sampling could not be performed at the time of the acute event because of hypoxemia. The patient initially received empirical antibiotics followed by corticosteroids, and clinical resolution occurred after the initiation of corticosteroids. The patient had received an immunecheckpoint inhibitor more than 2 months before entering the study. Because of the delayed occurrence of pneumonitis after immune-checkpoint therapy and pharmacologically relevant SAR260301 exposure documented in that patient (day 1 of cycle 1: C max , 8.8 lM total drug [t max , 0.5 hours]; approximately 50% pAkt inhibition in PRP at 2 hours; CT prolongation in platelet function PFA100 assay, 1.4-fold and >1.4-fold prolongation using collagen/ADP and collagen/epinephrine cartridges, respectively), the event was considered possibly related to study medication. The patient with a grade 3 GGT increase discontinued the study during cycle 1 because of disease progression, at which time the grade 3 GGT increase was documented in the context of liver metastases. The event resolved promptly after discontinuation of SAR260301 and without the initiation of another anticancer treatment. The event was considered possibly related to SAR260301. The MTD was not reached up to 440 mg/m 2 twice daily (patients received 700 mg twice daily or 1000 mg twice daily, according to their BSA).
Safety
All patients were evaluable for safety, and all had at least 1 AE; 13 patients had treatment-related AEs (Table 2  and Supporting Table 1 ; see online supporting information). The most frequently occurring, all-grade AEs reported by >10% of all patients, regardless of relation to treatment, were fatigue (52%); nausea (29%); diarrhea and abdominal pain (24% each); cough and vomiting (19% each); and decreased appetite, headache, constipation, myalgia, back pain, and increased GGT (14% each). The only grade 3 AEs reported by more than 1 patient were increased GGT (3 patients [14%], of which 1 was assessed as related), pleural effusion (10%), and disease progression (10%). The most frequently occurring, treatment-related AEs reported by >10% of patients were diarrhea, nausea and vomiting (14% each). Treatment-related grade 3 AEs were increased GGT and pneumonitis (5% each). The only grade 3 hematologic abnormalities were 3 episodes of lymphopenia (all grade 3). For these patients, lymphopenia was present at baseline (grade 3 in 1 patient and grade 2 in 2 patients), and there was no clear evidence of worsening while on treatment.
Nine patients (43%) had at least 1 SAE, and 1 event (grade 3 pneumonitis) was treatment-related. Nineteen patients discontinued the study because of disease progression, 1 discontinued because of physician's decision, and 1 discontinued because of physician's and patient's decision. Two patients (1 in the 100-mg once-daily cohort and 1 in the 600-mg twice-daily cohort) died as a result of disease progression. No patient had an AE that led to permanent discontinuation or dose modification of study treatment.
Pharmacokinetics
PK parameters (fasted conditions) were obtained for 21 patients during cycle 1 day 1 and for 15 patients during cycle 1 day 28. Among the 7 patients who received treatment during cycle 2 in fed conditions (moderate-fat breakfast), 6 were evaluable for the optional pilot foodeffect study (1 patient was excluded because of time deviation of drug intake compared with food). Blood SAR260301 PK parameters at days 1 and 28 in fasted conditions are presented in Supporting Table 2 (see online supporting information). SAR260301 was characterized by rapid absorption, with t max ranging from 0.5 to 1.5 hours post-oral dosing on both day 1 and day 28. Then, concentrations followed a biphasic elimination profile with a rapid decrease after C max and a slower terminal phase (corresponding to a mean apparent elimination half-life of approximately 5 hours determined after 100 mg daily). Overall, moderate-to-high variability was observed for C max with the coefficient of variation (CV) ranging from 29% to 116%. Low-to-high variability was observed for AUC s (CV: range, 20%-77%). SAR260301 PK profiles were similar between days 1 and 28, with no accumulation observed after repeated twicedaily administration for 28 days. On the basis of mean values, the apparent total body CL ss /F remained almost constant over the dose range tested (100-800 mg) after repeated, oral, twice-daily administration. Overall, CL ss / F was 165 liters per hour (CV, 42%). After a moderate-fat breakfast, a negative food effect was observed. In fed conditions, C max and AUC s decreased by 56% and 21%, respectively, for 6 patients who received doses from 100 to 400 mg twice daily, and the median t max was slightly delayed (Fig. 1 ) compared with fasted conditions (cycle 1 day 28). The PBPK model fit relatively well with the observed data for single-dose regimens from 100 to 600 mg and predicted the negative impact of food on SAR260301 exposure (Fig. 2) . The model predicted a systemic clearance of 60 liters per hour with no saturation, leading to 30% bioavailability. It was predicted that the food effect would be lost with high doses of SAR260301.
Pharmacodynamics
The ex vivo platelet pAkt IC 50 with PI3K isotype-specific inhibitors was 154 nM with SAR260301 (PI3Kb), 488 nM with SAR245409 (pan-PI3K), >3000 nM with GS-1101 (PI3Kd), and >10,000 nM with BYL719 (PI3Ka) (Supporting Table 3 ; see online supporting information). The predicted total SAR260301 plasma concentration for near-complete PI3K pathway inhibition (the concentration that inhibited 90% [IC 90 ]) was estimated at 7.5 lM based on ex vivo platelet pAkt inhibition evaluation using PI3Kb isoform-specific inhibitors and taking into account protein binding (Supporting Table 3 ; see online supporting information). In our study, the maximum inhibition of pAkt/tAkt in PRP was significantly correlated with exposure parameters on day 28 (Fig. 3) . The C max thresholds to reach 60% and 80% PI3K pathway inhibition were estimated at approximately 7 lM and 11 lM, respectively; and the AUC from 0 hours to 12 hours (AUC 0-12 ) thresholds to reach 60% and 80% PI3K pathway inhibition were approximately 12 lM x hour and 20 lM x hour, respectively (Fig. 3) . Sustained inhibition (6 hours) of the PI3K pathway consistently occurred with a C max 10 lM (n 5 2). In PBPK modeling, it was estimated that the minimum 7 lM SAR260301 concentration threshold would not be reached even with a of SAR260301 dose of 1.2 g twice daily (Fig. 2) . Figure 4 presents the distribution of fold increases in CT measured by PFA100 according to the C max for evaluable patients. Increasing SAR260301 exposure leads to a prolonged CT screening test. CT prolongation 1.3-fold was documented in 4 of 4 patients (100%) with a C max 10 lM, in 7 of 8 (87%) with a C max 6 lM, and in 6 of 12 (50%) with a C max <6 lM.
Efficacy
Twenty patients were evaluable for tumor response according to RECIST 1.1. Nineteen of these 20 patients had disease PTEN status documented by IHC in the most recent archival tumor tissue. Only 3 patients, all with colorectal cancer (CRC), had documented PTEN-null disease (Supporting Fig. 1) . No patient had a confirmed CR or partial response, and 15 patients progressed quickly after completion of the first or second cycle (Fig. 5) . Five patients had stable disease (including 1 with a PTEN-null tumor), 14 patients had progressive disease (including 2 with PTEN-null tumors), and 1 patient was not evaluable because of rapid disease progression.
It is interesting to note that a patient with PTENnull CRC stayed on study for almost 6 months (178 days), with stable disease as the best response. This patient had received 5 prior lines of treatment before coming on 
Abbreviations: AE, adverse event; BID, twice daily; GGT, g-glutamyltransferase; QD, once daily. a The 440 mg/m 2 BID dose category included 1 patient who received 700 mg BID and another who received 1000 mg BID.
Original Article study, with progressive disease as the best response with the 2 most recent treatment regimens (combined folinic acid, oxaliplatin, and fluorouracil [FOLFOX]/bevacizumab, then irinotecan/bevacizumab). The patient received 440 mg/m 2 twice daily and also received 1000 mg twice daily according to his BSA. SAR260301 C max exceeded 10 lM, and sustained (at least 6 hours) >80% pAkt inhibition was documented in PRP.
DISCUSSION
In this first-in-human study, we investigated the MTD, safety, PK, pharmacodynamics, and efficacy of the selective PI3Kb inhibitor SAR260301. The MTD of SAR260301 was not reached up to 440 mg/m 2 twice daily, although safety at the highest dose level tested was not fully evaluated because of the low number of patients treated. The most frequently occurring AEs were gastrointestinal, consistent with trials of other PI3K inhibitors. Of note, the AEs observed in this study did not include hyperglycemia, which is frequently observed with pan-PI3K inhibitors. 15 These results suggest that the in vivo effect of SAR260301 is limited to the PI3Kb isoform, and does not occur with other PI3K isoforms.
The PI3Kb isoform is selectively activated in many tumors bearing PTEN loss, suggesting that inhibiting this isoform might be beneficial in PTEN-negative tumors. 2, [16] [17] [18] [19] [20] [21] It has been demonstrated that SAR260301 blocks PI3K signaling in PTEN-negative tumors and confers synergistic activity when combined with BRAF or MAPK/ERK kinase inhibitors against PTEN-negative/ BRAF V600E melanoma models. 9 In this study, there were Phase I PI3Kb Inhibitor SAR260301/B edard et al
Cancer January 15, 2018 no objective responses in a nonselected population; however, 1 heavily pretreated patient with CRC who had a PTEN-null tumor had stable disease that lasted for 6 months. Other selective PI3Kb inhibitors, AZD8186 (NCT01884285) and GSK2636771 (NCT01458067) are currently being tested in patients with PTEN-negative tumors; preliminary phase 1 results from the latter study suggest that there may be a clinical benefit for this patient population.
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SAR260301 was rapidly absorbed (t max , 0.5-1.5 hours) and exhibited a biphasic elimination profile with a rapid decrease in concentration after C max . No major accumulation or deviation from dose proportionality was observed. Food intake was associated with a decrease in exposure.
SAR260301 activity was assessed using a plateletinhibition assay, which can serve as a surrogate biomarker assay in patients with cancer. 11 The predicted SAR260301 concentrations required to completely inhibit the PI3K pathway were derived from an ex vivo platelet pAktinhibition assay. Biologically active concentrations (based on preclinical modeling) were reached at the highest doses tested; however, SAR260301 was rapidly cleared, and exposure associated with antitumor activity in preclinical studies was not maintained. The PBPK simulations indicated that, at the doses most patients would be able to receive, they would not reach sufficient exposure to achieve the sustained 80% inhibition of PI3Kb activity that would be required for antitumor activity. The relation between systemic drug exposure and corresponding exposures in the platelet and the tumor compartments should be explored in future studies.
The study was terminated prematurely, because the PK data indicated a rapid elimination associated with the prediction of a nonsaturable SAR260301 apparent clearance, preventing achievement of the minimum exposure required for a sustained pharmacodynamic effect. The MTD was not identified, and no further development of SAR260301 is planned. This work underlines the importance of pharmacologic assessments in early drug development. Preclinical efficacy threshold assessments, PK sampling, and PK/pharmacodynamic modeling in early phase clinical trials are powerful instruments for identifying which compounds should not be explored further in the clinical settings.
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